Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Pre-Tax Margin
Income before tax as a percentage of revenue.
Quest Diagnostics IncorporatedNYSE: DGX
Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026
Pre-tax margin widens to 13.4%
Pre-tax margin was 13.4% in Q3 FY2026, up 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 12.7%, up 0.4 pp year over year. Over 3 fiscal years it narrowed by 0.6 pp.
Context
- Pre-tax margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 12.3%
- Year-over-year change
- +0.2pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.3% | +0.2pp |
| FY2024 | 2024-12-31 | 12.1% | -0.4pp |
| FY2023 | 2023-12-31 | 12.5% | -0.4pp |
| FY2022 | 2022-12-31 | 12.9% | -11.9pp |
| FY2021 | 2021-12-31 | 24.8% | — |
Pre-Tax Margin vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's LTM Sep 2026 pre-tax margin of 12.7% is the 3rd highest of the 9 companies compared; the peer median is 5.2%.
- Its year-over-year change of +0.4 pp is the 6th highest of 9, against a peer median of +0.9 pp.
- Over three fiscal years its change of -0.6 pp compares with a peer median of +27.3 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 22.6% | -10.0 pp | +119.6 pp | |
| LTM Jun 2026 | 22.0% | -2.0 pp | -0.5 pp | |
| LTM Sep 2026 | 12.7% | +0.4 pp | -0.6 pp | |
| LTM Jul 2026 | 9.0% | -2.3 pp | -10.3 pp | |
| LTM Jun 2026 | 8.6% | +1.4 pp | -2.5 pp | |
| LTM Sep 2026 | 1.8% | +0.4 pp | -1.4 pp | |
| LTM Jun 2026 | -9.3% | +3.6 pp | +55.0 pp | |
| LTM Sep 2026 | -38.0% | +6.1 pp | +102.8 pp | |
| LTM Jun 2026 | -320.4% | +125.4 pp | +9432.3 pp | |
| Peer median (excluding DGX) | 5.2% | +0.9 pp | +27.3 pp | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 10.79B | 9.88B | 9.25B | 9.87B | 11.04B |
| Cost of Revenue | 6.58B | 6.45B | 6.2B | 6.63B | 7.51B |
| Gross Profit | 4.21B | 3.43B | 3.07B | 3.24B | 3.52B |
| Gross Margin | 39.0% | 34.7% | 33.2% | 32.9% | 31.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.73B | 1.87B | 1.62B | 1.77B | 1.97B |
| Operating Expenses | 1.83B | 2.01B | 1.81B | 1.9B | 1.92B |
| Depreciation & Amortization | 408M | 437M | 439M | 493M | 570M |
| EBITDA | 3.16B | 1.82B | 1.73B | 1.89B | 2.19B |
| EBITDA Margin | 29.3% | 18.4% | 18.7% | 19.2% | 19.9% |
| Operating Income | 2.38B | 1.43B | 1.26B | 1.35B | 1.6B |
| Operating Margin | 22.1% | 14.4% | 13.6% | 13.6% | 14.5% |
| Interest Income | 1M | 10M | 11M | 25M | 13M |
| Interest Expense | 152M | 148M | 163M | 226M | 277M |
| Other Income / Expenses | 296M | (149M) | (106M) | (152M) | (243M) |
| Income Before Tax | 2.68B | 1.28B | 1.16B | 1.19B | 1.36B |
| Pre-Tax Margin | 24.8% | 12.9% | 12.5% | 12.1% | 12.3% |
| Income Tax Expense | 597M | 264M | 248M | 273M | 314M |
| Net Income | 2B | 946M | 854M | 871M | 992M |
| Net Margin | 18.5% | 9.6% | 9.2% | 8.8% | 9.0% |
| EPS (Basic) | 15.90 | 8.12 | 7.59 | 7.80 | 8.87 |
| EPS (Diluted) | 15.53 | 7.98 | 7.52 | 7.69 | 8.75 |
| Weighted Avg Shares | 125M | 116M | 112M | 111M | 111M |
| Weighted Avg Shares (Diluted) | 128M | 118M | 113M | 113M | 113M |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.